Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) reported positive data from the late-stage trial, which assessed Dupixent ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

The long-running “Du More” motif for Sanofi and Regeneron’s immunology blockbuster Dupixent is looking to make a splash with its first new commercial of 2023. In the 60-second spot, “It's Possible: ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

Q3 2025 Management View CEO Leonard Schleifer reported "double-digit net sales growth for 3 of our leading products," ...

Regeneron and Sanofi are at it again with their ongoing Dupixent DTC campaign dubbed DU More. The pair of drugmakers rolled out the latest iteration of the campaign on Monday morning, right in time ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

Dupixent started 2023 the way it ended 2022: at the top. The severe asthma treatment had the largest impressions share of voice (SOV) among Rx and over-the-counter pharma brands in January, totaling ...

Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...